ATE516043T1 - Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden - Google Patents

Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden

Info

Publication number
ATE516043T1
ATE516043T1 AT06824316T AT06824316T ATE516043T1 AT E516043 T1 ATE516043 T1 AT E516043T1 AT 06824316 T AT06824316 T AT 06824316T AT 06824316 T AT06824316 T AT 06824316T AT E516043 T1 ATE516043 T1 AT E516043T1
Authority
AT
Austria
Prior art keywords
inhibitor
reperfusion injury
prevention
ischemic reperfusion
reperfusion
Prior art date
Application number
AT06824316T
Other languages
English (en)
Inventor
Maurice Mannesse
Johannes Henricus Nuijens
Frank Pieper
Simoni Maria Grazia De
Gijsbertus Johannes Ziere
Original Assignee
Pharming Intellectual Pty Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Pty Bv filed Critical Pharming Intellectual Pty Bv
Application granted granted Critical
Publication of ATE516043T1 publication Critical patent/ATE516043T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT06824316T 2005-12-21 2006-12-19 Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden ATE516043T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05112630 2005-12-21
US76094406P 2006-01-23 2006-01-23
PCT/NL2006/050321 WO2007073186A2 (en) 2005-12-21 2006-12-19 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
ATE516043T1 true ATE516043T1 (de) 2011-07-15

Family

ID=38016640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824316T ATE516043T1 (de) 2005-12-21 2006-12-19 Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden

Country Status (15)

Country Link
US (3) US8071532B2 (de)
EP (2) EP1965831B1 (de)
JP (2) JP5394748B2 (de)
KR (1) KR101508668B1 (de)
AT (1) ATE516043T1 (de)
AU (1) AU2006327989B2 (de)
CA (1) CA2632400C (de)
CY (2) CY1112452T1 (de)
DK (1) DK2380587T3 (de)
HR (2) HRP20110622T1 (de)
IL (2) IL192180A (de)
NZ (1) NZ568749A (de)
PL (2) PL2380587T3 (de)
SI (1) SI2380587T1 (de)
WO (1) WO2007073186A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551987A1 (de) * 2002-10-17 2005-07-13 Pharming Intellectual Property B.V. Protein-modifikatoin
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US8703136B2 (en) * 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
JP5423266B2 (ja) * 2009-09-14 2014-02-19 富士電機株式会社 デジタル制御スイッチング電源装置
WO2012120128A1 (en) * 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (de) * 2011-03-09 2012-09-12 CSL Behring GmbH Faktor XII-Hemmer zur Behandlung von schleichender Ischämie und Ischämie in anderen Organen
KR101956585B1 (ko) 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104080474B (zh) * 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经***继发性水肿中的应用
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
DK2961422T3 (en) 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
LT2968434T (lt) 2013-03-15 2017-09-25 Shire Viropharma Incorporated C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui
EP3013366B1 (de) * 2013-06-28 2021-08-25 CSL Behring GmbH Kombinationstherapie mit einem faktor xii-hemmer und einem c1-hemmer
EP3708226A1 (de) * 2014-11-03 2020-09-16 Thrombolytic Science, LLC Verfahren und zusammensetzungen zur sicheren und wirksamen thrombolyse
KR20180006379A (ko) 2015-04-06 2018-01-17 바이오버라티브 유에스에이 인코포레이티드 인간화 항-c1s 항체 및 이들의 이용 방법
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
JP7189767B2 (ja) * 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
WO2018024873A1 (en) 2016-08-05 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN109641031A (zh) 2016-08-23 2019-04-16 德国杰特贝林生物制品有限公司 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
US20200276283A1 (en) 2017-09-15 2020-09-03 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210005549A (ko) 2018-02-28 2021-01-14 파밍 인텔렉츄얼 프라퍼티 비.브이. 전자간증의 치료 및 예방
US20210380636A1 (en) 2018-10-17 2021-12-09 Csl Behring Gmbh Process for purifying c1-inh
WO2021001525A1 (en) 2019-07-04 2021-01-07 Csl Behring Gmbh Process for purifying c1-inh
KR102191500B1 (ko) 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (de) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Verwendung von c1-esterase-inhibitoren zur behandlung von akuter atemnot im zusammenhang mit virusinfektionen
KR102217607B1 (ko) 2020-06-01 2021-02-18 국립낙동강생물자원관 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko) 2020-06-30 2020-12-15 주식회사 에이치비헬스케어 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
AU2021381360A1 (en) 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069894A2 (en) 1999-05-14 2000-11-23 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
CA2398707C (en) * 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
JP2004100982A (ja) * 2002-09-05 2004-04-02 Denso Corp 熱交換器
EP1551987A1 (de) 2002-10-17 2005-07-13 Pharming Intellectual Property B.V. Protein-modifikatoin
WO2004100982A1 (en) 2003-05-16 2004-11-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

Also Published As

Publication number Publication date
CY1112452T1 (el) 2015-12-09
IL192180A0 (en) 2009-02-11
EP2380587A1 (de) 2011-10-26
JP5394748B2 (ja) 2014-01-22
US20120088728A1 (en) 2012-04-12
WO2007073186A2 (en) 2007-06-28
US8071532B2 (en) 2011-12-06
IL228954A (en) 2016-10-31
PL1965831T3 (pl) 2011-12-30
US20080305993A1 (en) 2008-12-11
EP1965831B1 (de) 2011-07-13
AU2006327989A1 (en) 2007-06-28
DK2380587T3 (en) 2017-12-04
JP2013126992A (ja) 2013-06-27
CY1119818T1 (el) 2018-06-27
CA2632400A1 (en) 2007-06-28
IL228954A0 (en) 2013-12-31
PL2380587T3 (pl) 2018-03-30
AU2006327989B2 (en) 2012-06-07
IL192180A (en) 2013-10-31
EP1965831A2 (de) 2008-09-10
KR20080098001A (ko) 2008-11-06
US8415288B2 (en) 2013-04-09
KR101508668B1 (ko) 2015-04-06
EP2380587B1 (de) 2017-10-25
NZ568749A (en) 2011-05-27
HRP20110622T1 (hr) 2011-09-30
JP2009520815A (ja) 2009-05-28
WO2007073186A3 (en) 2007-08-09
SI2380587T1 (en) 2018-03-30
US20130244941A1 (en) 2013-09-19
CA2632400C (en) 2016-06-07
HRP20171738T1 (hr) 2018-01-26
US9211318B2 (en) 2015-12-15

Similar Documents

Publication Publication Date Title
ATE516043T1 (de) Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
EA200602220A1 (ru) Новое применение пептидных соединений для лечения амиотрофического бокового склероза
MX2009005185A (es) Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus.
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
MY146509A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
ATE524741T1 (de) Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
WO2006063048A3 (en) Ibudilast for treating neuropathic pain and associated syndromes
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
GEP20125683B (en) Serine proteases inhibitors for hcv infections treatment
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
ECSP044935A (es) Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
IN2014DN08578A (de)
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
DE60335175D1 (de) Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
DE602006008447D1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
CY1110074T1 (el) Ενωσεις βενζιμιδαζολιου
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
ATE547396T1 (de) Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1965831

Country of ref document: EP